Wedbush Research Analysts Cut Earnings Estimates for RVMD

Key Points

• Wedbush analysts have cut Revolution Medicines' Q3 2025 earnings estimate from $0.12 per share to $0.02 per share, maintaining an "Outperform" rating with a price objective of $73.00.
• The company reported Q2 results with earnings per share of ($1.31), missing analysts' estimates by $0.37, despite a slight quarterly revenue increase.
• Institutional investor interest remains high, with 94.34% of shares currently held by investors and hedge funds increasing their positions in Revolution Medicines.

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Stock analysts at Wedbush decreased their Q3 2025 earnings estimates for Revolution Medicines in a report released on Wednesday, August 6th. Wedbush analyst R. Driscoll now forecasts that the company will earn $0.02 per share for the quarter, down from their prior estimate of $0.12. Wedbush has a "Outperform" rating and a $73.00 price objective on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines' Q4 2025 earnings at ($1.33) EPS, FY2025 earnings at ($3.76) EPS, Q1 2026 earnings at ($1.37) EPS, Q2 2026 earnings at ($1.39) EPS, Q3 2026 earnings at ($1.43) EPS, Q4 2026 earnings at ($1.45) EPS, FY2026 earnings at ($5.64) EPS, FY2027 earnings at ($4.08) EPS, FY2028 earnings at ($3.51) EPS and FY2029 earnings at $1.47 EPS.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.37). The firm's quarterly revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.81) EPS.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reiterated a "buy" rating and issued a $72.00 target price (down from $73.00) on shares of Revolution Medicines in a research report on Wednesday, May 14th. Needham & Company LLC reduced their target price on shares of Revolution Medicines from $57.00 to $56.00 and set a "buy" rating for the company in a research report on Thursday. Guggenheim reiterated a "buy" rating and issued a $80.00 target price on shares of Revolution Medicines in a research report on Wednesday, June 25th. Oppenheimer increased their target price on shares of Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Revolution Medicines in a research report on Tuesday, July 15th. They issued a "buy" rating and a $65.00 target price for the company. Eleven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $68.82.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD opened at $35.00 on Monday. The firm has a 50-day simple moving average of $38.42 and a 200-day simple moving average of $38.74. The stock has a market capitalization of $6.54 billion, a price-to-earnings ratio of -7.78 and a beta of 1.16. The company has a quick ratio of 11.79, a current ratio of 11.79 and a debt-to-equity ratio of 0.13. Revolution Medicines has a 52 week low of $29.17 and a 52 week high of $62.40.

Institutional Investors Weigh In On Revolution Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in Revolution Medicines by 11.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,221 shares of the company's stock worth $232,000 after purchasing an additional 615 shares during the last quarter. Russell Investments Group Ltd. increased its position in Revolution Medicines by 11.4% during the fourth quarter. Russell Investments Group Ltd. now owns 4,243 shares of the company's stock worth $186,000 after purchasing an additional 434 shares during the last quarter. SG Americas Securities LLC increased its position in Revolution Medicines by 516.0% during the first quarter. SG Americas Securities LLC now owns 18,103 shares of the company's stock worth $640,000 after purchasing an additional 15,164 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Revolution Medicines by 51.8% during the fourth quarter. Wells Fargo & Company MN now owns 88,327 shares of the company's stock worth $3,863,000 after buying an additional 30,155 shares during the period. Finally, Baker BROS. Advisors LP boosted its stake in Revolution Medicines by 4.9% during the fourth quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company's stock worth $347,163,000 after buying an additional 367,882 shares during the period. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.